Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2019

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Pruritus
  • Focus Registrational; Therapeutic Use
  • Sponsors Menlo Therapeutics

    • Most Recent Events

    • 15 Jan 2019 According to a Menlo Therapeutics media release, data from the trial is expected by the first quarter of 2020.
    • 08 Nov 2018 New source identified and integrated (European Clinical Trials Database: EudraCT2017-004210-25)
    • 17 Sep 2018 According to a Menlo Therapeutics media release, results from this trial is expected in the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top